Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CHC001
MIFTS: 50

Chickenpox

Categories: Immune diseases, Infectious diseases, Skin diseases
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Chickenpox

About this section

MalaCards integrated aliases for Chickenpox:

Name: Chickenpox 12 77 44 45 15 17 74 3 64
Varicella 12 56 15

Classifications:

MalaCards categories:
Global: Infectious diseases
Anatomical: Skin diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:8659
ICD9CM 36 052
MeSH 45 D002644
NCIt 51 C97132
SNOMED-CT 69 38907003
ICD10 34 B01 B01.8 B01.9
UMLS 74 C0008049
Sources

Summaries for Chickenpox

About this section
MedlinePlus : 44 Chickenpox is an infection caused by the varicella-zoster virus. Most cases are in children under age 15, but older children and adults can get it. It spreads very easily from one person to another. The classic symptom of chickenpox is an uncomfortable, itchy rash. The rash turns into fluid-filled blisters and eventually into scabs. It usually shows up on the face, chest, and back and then spreads to the rest of the body. Other symptoms include Fever Headache Tiredness Loss of appetite Chickenpox is usually mild and lasts 5 to 10 days. Calamine lotions and oatmeal baths can help with itching. Acetaminophen can treat the fever. Do not use aspirin for chickenpox; that combination can cause Reye syndrome. Chickenpox can sometimes cause serious problems. Adults, babies, teenagers, pregnant women, and those with weak immune systems tend to get sicker from it. They may need to take antiviral medicines. Once you catch chickenpox, the virus usually stays in your body. You probably will not get chickenpox again, but the virus can cause shingles in adults. A chickenpox vaccine can help prevent most cases of chickenpox, or make it less severe if you do get it. Centers for Disease Control and Prevention

MalaCards based summary : Chickenpox, also known as varicella, is related to salivary gland disease and fasciitis, and has symptoms including fever, anorexia and myalgia. An important gene associated with Chickenpox is GYPC (Glycophorin C (Gerbich Blood Group)). The drugs Ethanol and Foscarnet have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and testes.

Disease Ontology : 12 A viral infectious disease that results in infection located in skin, has material basis in Human herpesvirus 3, which is transmitted by direct contact with secretions from the rash, or transmitted by droplet spread of respiratory secretions. The infection has symptom anorexia, has symptom myalgia, has symptom nausea, has symptom fever, has symptom headache, has symptom sore throat, and has symptom blisters.

PubMed Health : 64 About chickenpox: Chickenpox is a highly contagious viral infection which mainly affects children. Typical symptoms include a very itchy skin rash with red blisters and a mild fever. Because most children are now vaccinated, chickenpox (also referred to as varicella) is much less common than it was in the past.If someone comes down with chickenpox, they are contagious after just one or two days, which is before they have a visible rash. But taking precautions and improving hygiene can help to avoid infecting others. Although chickenpox is unpleasant, it rarely has any serious consequences in children who are otherwise healthy. But it may become more severe in newborns and adults, as well as people who have a weakened immune system.

Wikipedia : 77 Chickenpox, also known as varicella, is a highly contagious disease caused by the initial infection with... more...

Sources

Related Diseases for Chickenpox

About this section

Diseases related to Chickenpox via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 550)
# Related Disease Score Top Affiliating Genes
1 salivary gland disease 31.9 AMHR2 DPT
2 fasciitis 30.7 ACTC1 MUC1
3 pneumothorax 30.0 BLVRA MUC1 PGR
4 varicella, severe recurrent 12.1
5 herpes zoster 12.0
6 congenital varicella syndrome 11.8
7 geniculate herpes zoster 11.7
8 postherpetic neuralgia 11.6
9 myoclonus and ataxia 11.5
10 microcephaly 11.3
11 cytomegalovirus infection 11.2
12 immunodeficiency 50 11.1
13 immunodeficiency 24 11.1
14 cytomegalic inclusion disease 11.0
15 neurological consequences of cytomegalovirus infection 11.0
16 infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovascular malformations 11.0
17 idiopathic cd4-positive t-lymphocytopenia 11.0
18 adult-onset immunodeficiency with anti-interferon-gamma autoantibodies 11.0
19 torch syndrome 11.0
20 pneumonia 10.5
21 breast mucoepidermoid carcinoma 10.4 MUC1 PGR
22 breast scirrhous carcinoma 10.4 MUC1 PGR
23 endosalpingiosis 10.4 MUC1 PGR
24 calcifying aponeurotic fibroma 10.4 ACTC1 PGR
25 cystadenoma 10.4 MUC1 PGR
26 bizarre leiomyoma 10.4 ACTC1 PGR
27 myxoid leiomyosarcoma 10.4 ACTC1 PGR
28 cutaneous leiomyosarcoma 10.4 ACTC1 MUC1
29 endometrial mucinous adenocarcinoma 10.4 MUC1 PGR
30 apocrine adenocarcinoma 10.4 MUC1 PGR
31 parachordoma 10.4 ACTC1 MUC1
32 syringocystadenoma papilliferum 10.4 ACTC1 MUC1
33 benign metastasizing leiomyoma 10.4 ACTC1 PGR
34 clear cell meningioma 10.4 MUC1 PGR
35 measles 10.4
36 ossifying fibromyxoid tumor 10.4 ACTC1 MUC1
37 adenofibroma 10.4 ACTC1 MUC1
38 glycogen-rich clear cell breast carcinoma 10.4 ACTC1 PGR
39 spiradenoma 10.4 ACTC1 MUC1
40 ischemic fasciitis 10.4 ACTC1 MUC1
41 sertoli cell tumor 10.4 MUC1 PGR
42 dermoid cyst 10.4 MUC1 PGR
43 reticulum cell sarcoma 10.4 ACTC1 MUC1
44 sertoli-leydig cell tumor 10.4 MUC1 PGR
45 sclerosing hemangioma 10.4 MUC1 PGR
46 pancreatic mucinous cystadenoma 10.4 MUC1 PGR
47 spindle cell sarcoma 10.4 ACTC1 MUC1
48 smooth muscle tumor 10.3 ACTC1 PGR
49 dendritic cell tumor 10.3 ACTC1 MUC1
50 mammary paget's disease 10.3 MUC1 PGR

Graphical network of the top 20 diseases related to Chickenpox:



Diseases related to Chickenpox
Sources

Symptoms & Phenotypes for Chickenpox

About this section

Symptoms:

12
  • • fever
  • • anorexia
  • • myalgia
  • • headache
  • • nausea
  • • sore throat
  • • blisters

UMLS symptoms related to Chickenpox:


fever, pruritus, exanthema
Sources

Drugs & Therapeutics for Chickenpox

About this section

PubMedHealth treatment related to Chickenpox: 64

The treatment usually focuses on relieving the symptoms of chickenpox. In more severe cases, or if there is a greater risk of complications, antiviral drugs can be used to fight off the virus. Lotions, gels and powders are often applied in order to relieve itching and dry out the blisters. Most of them contain tanins, zinc, menthol or polidocanol. Sometimes oral medication like antihistamines is also recommended to stop the itching. But there is no good-quality scientific research on how effective they are.Symptoms like fever or aching muscles can be relieved using medicine that contains acetaminophen (paracetamol). The painkiller ibuprofen is not suitable for children with chickenpox. Children and teenagers should only take acetylsalicylic acid (ASA, the drug in medicines like Aspirin) if it has been prescribed by a doctor, and only as a last resort. This is because it can cause a rare but dangerous side effect called Reye’s syndrome in children and teenagers.

Drugs for Chickenpox (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 222)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4 64-17-5 702
2
Foscarnet Approved Phase 4 63585-09-1, 4428-95-9 3415
3
Acyclovir Approved Phase 4,Phase 3,Phase 2 59277-89-3 2022
4
Budesonide Approved Phase 4 51333-22-3 63006 5281004
5
Gabapentin Approved, Investigational Phase 4,Not Applicable 60142-96-3 3446
6
Tofacitinib Approved, Investigational Phase 4,Phase 2 477600-75-2
7
Methotrexate Approved Phase 4,Phase 3,Phase 2 1959-05-2, 59-05-2 126941
8 Vedolizumab Approved Phase 4 943609-66-3
9
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 2 148553-50-8 5486971
10
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
11
Certolizumab pegol Approved Phase 4 428863-50-7
12
Infliximab Approved Phase 4,Phase 3 170277-31-3
13
Mercaptopurine Approved Phase 4 50-44-2 667490
14
Azathioprine Approved Phase 4 446-86-6 2265
15
Adalimumab Approved Phase 4 331731-18-1 16219006
16
Calcium Approved, Nutraceutical Phase 4,Phase 2,Phase 1 7440-70-2 271
17
Phosphonoacetic Acid Experimental Phase 4 4408-78-0 546
18 Vaccines Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
19 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
20 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
21 Anti-Retroviral Agents Phase 4,Phase 2,Phase 1
22 Reverse Transcriptase Inhibitors Phase 4
23 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Immunoglobulins Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
26 Antibodies Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
27 valacyclovir Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
29 Anti-Infective Agents, Local Phase 4
30 Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
31 Respiratory System Agents Phase 4,Phase 3,Phase 2
32 Bronchodilator Agents Phase 4,Phase 3
33 glucocorticoids Phase 4,Phase 3,Phase 2,Not Applicable
34 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
35 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Anti-Asthmatic Agents Phase 4,Phase 3
37 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
38 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 2,Not Applicable
41 Pharmaceutical Solutions Phase 4,Phase 3,Phase 1,Phase 2
42 Anti-Anxiety Agents Phase 4,Phase 2,Not Applicable
43 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Excitatory Amino Acids Phase 4,Phase 2,Not Applicable
45 Tranquilizing Agents Phase 4,Phase 2,Not Applicable
46 Anticonvulsants Phase 4,Phase 2,Not Applicable
47 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Not Applicable
48 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
49 Excitatory Amino Acid Antagonists Phase 4,Phase 2,Not Applicable
50 Antimanic Agents Phase 4,Not Applicable

Interventional clinical trials:

(show top 50) (show all 364)
# Name Status NCT ID Phase Drugs
1 The Safety, Immunogenicity and Immune Effect Research of the Varicella Vaccine After the 2nd Dose Vaccination Unknown status NCT01830283 Phase 4
2 Immune Persistence After Inoculated With One-dose Freeze-Dried Live Attenuated Varicella Vaccine in Children Vaccine in Children Unknown status NCT01982409 Phase 4
3 The Safety and Immunogenicity Research of Live Attenuated Varicella Vaccine After the 2 Doses Vaccination Unknown status NCT01866566 Phase 4
4 Study on Effectiveness of 2-dose Live Attenuated Varicella Vaccine Unknown status NCT02146469 Phase 4
5 Pilot Study to Describe Immune Responses of Healthy Women Following Immunization With Varicella Zoster Virus Vaccine Unknown status NCT02514018 Phase 4
6 Immunodeficiency in Cartilage-hair Hypoplasia: Sub-project on Safety of Vaccination Against Chickenpox Unknown status NCT02383797 Phase 4
7 Safety and Immunogenicity of Zostavax Vaccine in Patients Undergoing Living Donor Kidney Transplantation Unknown status NCT00940940 Phase 4
8 Efficacy and Safety of Foscarnet Sodium and Sodium Chloride Injection in Patients With Herpes Zoster Unknown status NCT02151240 Phase 4 Foscarnet Sodium;Acyclovir
9 Immunogenicity and Safety of 2 Doses of Live Attenuated Varicella Vaccine Completed NCT02173899 Phase 4
10 Immunogenicity and Safety Study of 2 Doses of Live Attenuated Varicella Vaccine Completed NCT01817270 Phase 4
11 Safety of a Second Dose of Biken's Varicella Vaccine Completed NCT00830648 Phase 4
12 Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine Completed NCT01815073 Phase 4
13 Safety and Immunogenicity Study of Live Attenuated Vaccine Against Varicella Without Gelatin Completed NCT01684072 Phase 4
14 Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00126997 Phase 4
15 Effective Study of Live Attenuated Varicella Vaccine to Treat Severe Resistant Psoriasis Completed NCT01356004 Phase 4 live attenuated chicken pox vaccine;saline, efficacy
16 Varicella Vaccination With Pulmicort Completed NCT00641446 Phase 4 budesonide;varicella zoster virus
17 The Immunogenicity of Varicella-zoster Virus Vaccine in HIV-infected Children Completed NCT01138215 Phase 4
18 T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020 Completed NCT01911065 Phase 4
19 Zostavax® at Minimum Release Specification Approaching Expiry (V211-044) Completed NCT00681031 Phase 4
20 Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED) Completed NCT00326183 Phase 4
21 Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067) Completed NCT00312858 Phase 4
22 Placebo Controlled Evaluation of the Cell Mediated Immune Response of Cirrhotic Subjects to Zostavaxâ„¢ Completed NCT02958345 Phase 4
23 Effectiveness Assessment of Vaccinating Schoolchildren Against Influenza Completed NCT01693380 Phase 4
24 Safety Study of a Refrigerator-stable Formulation of VARIVAX® Completed NCT00432731 Phase 4
25 Palatability Testing of a New Paediatric Formulation of Valacyclovir Completed NCT01682109 Phase 4 Valacyclovir
26 ZOSTAVAXâ„¢ Safety and Immunogenicity in Korean Adults (V211-034) Completed NCT01556451 Phase 4
27 Study of the Influence of Vaccination in HIV Viral Load and Immunologic Responses Against HIV Completed NCT00329251 Phase 4
28 A Study of Vacyless® Versus Valtrex® in Patients With Herpes Zoster Completed NCT02152800 Phase 4 valacyclovir hydrocholoride
29 ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020) Completed NCT00550745 Phase 4
30 Acupuncture in Herpes Zoster Neuralgia (ACUZoster) Completed NCT00885586 Phase 4 gabapentine
31 Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A Vaccine Recruiting NCT03330171 Phase 4
32 Safety and Immunogenicity of Non-live, Recombinant Subunit Herpes Zoster Vaccine Before and After Lung Transplantation Recruiting NCT03493776 Phase 4
33 Safety and Tolerability of Herpes Zoster Vaccine Rheumatologic Patients Recruiting NCT03016884 Phase 4
34 Immune Response to Shingles Vaccination Recruiting NCT02624375 Phase 4 Zoster Vaccine Live
35 Zoster Eye Disease Study Recruiting NCT03134196 Phase 4 Masked Placebo;Masked Oral Valacyclovir
36 Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab Recruiting NCT03798691 Phase 4
37 Efficacy of Pregabalin for the Treatment of Acute Herpetic Neuralgia Recruiting NCT03809702 Phase 4 Pregabalin;Placebo
38 Safety and Immunogenicity of a Zoster Vaccine in SLE Active, not recruiting NCT02477150 Phase 4
39 Vaccinating Children After Chemotherapy Active, not recruiting NCT02447718 Phase 4
40 Persistence of Varicella Immunity in Hospital Employees Receiving Varicella Vaccine Not yet recruiting NCT02026089 Phase 4
41 Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination Not yet recruiting NCT03350698 Phase 4
42 Subunit Vaccine Against Herpes Zoster in RA Patients Treated With JAK-inhibitors (VACCIMIL-ZOSTER) Not yet recruiting NCT03886038 Phase 4
43 Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib Not yet recruiting NCT03591770 Phase 4
44 Varicella Zoster Vaccine in Patients With Plaque Psoriasis Treated With Biologic Therapy Terminated NCT02408159 Phase 4 Varicella Zoster Vaccine;Placebo
45 Serological Evaluation of Varicella and Hepatitis A Vaccines Using Injector Delivery Unknown status NCT00926419 Phase 2, Phase 3
46 Immunity Against Varicella in Pediatric Orthotopic Liver Transplantation Recipients Unknown status NCT00492739 Phase 2, Phase 3
47 The Safety of Oka Varicella in Children Prior to Solid Organ Transplantation Unknown status NCT00213304 Phase 3
48 Immunogenicity and Safety of NBP608 Compared to Varivax in Healthy Children 12 Months to 12 Years of Age Unknown status NCT03114943 Phase 3
49 Efficacy of Oral Famciclovir Versus Aciclovir Treatment in Patients With Herpes Zoster Unknown status NCT01327144 Phase 3 Famciclovir;Aciclovir
50 A Blind, Randomized and Controlled Study of Live Attenuated Varicella Vaccines Completed NCT02981836 Phase 3

Search NIH Clinical Center for Chickenpox

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: chickenpox

Sources

Genetic Tests for Chickenpox

About this section
Sources

Anatomical Context for Chickenpox

About this section

MalaCards organs/tissues related to Chickenpox:

42
Skin, T Cells, Testes, Brain, Liver, Lung, Bone

The Foundational Model of Anatomy Ontology organs/tissues related to Chickenpox:

20
Skin
Sources

Publications for Chickenpox

About this section

Articles related to Chickenpox:

(show top 50) (show all 3256)
# Title Authors Year
1
Visceral disseminated varicella zoster virus infection with brachial plexus neuritis detected by fluorodeoxyglucose positron emission tomography and computed tomography. ( 30879980 )
2019
2
Increased risk of varicella-zoster virus infection in patients with breast cancer after adjuvant radiotherapy: A population-based cohort study. ( 30625182 )
2019
3
Hospital Onset Varicella Central Nervous System Vasculitis in a Patient with HIV Infection. ( 30715900 )
2019
4
Chickenpox in a Vaccinated Adult. ( 30623385 )
2019
5
Epidemiological and clinical characteristics and the approach to infant chickenpox in primary care. ( 30767142 )
2019
6
A case of varicella zoster encephalitis with glossopharyngeal and vagus nerve injury as primary manifestation combined with medulla lesion. ( 30880528 )
2019
7
Characterization of Virus-specific Immune Response During Varicella Zoster Virus Encephalitis in a Young Adult. ( 30668661 )
2019
8
Anti-NMDAR encephalitis with concomitant varicella zoster virus detection and nonteratomatous malignancy. ( 30697587 )
2019
9
Hemorrhagic shock resulting from varicella zoster gastritis in a non-immunocompromised patient. ( 30690214 )
2019
10
Differences in the likelihood of acyclovir resistance-associated mutations in the thymidine kinase genes of herpes simplex virus 1 and varicella-zoster virus. ( 30858222 )
2019
11
Herpes zoster onset 9 years after first varicella zoster vaccination in a 11 year old child - a case report. ( 30887925 )
2019
12
Evaluation of VZV-specific Cell-mediated Immunity by Interferon-gamma ELISA in Adults ≥50 Years of Age Administered a Herpes Zoster Vaccine. ( 30613990 )
2019
13
Severe Herpes Zoster Following Varicella Vaccination in Immunocompetent Young Children. ( 30628536 )
2019
14
Models for optimally controlling varicella and herpes zoster by varicella vaccination: a comparative study. ( 30652233 )
2019
15
The impact of childhood varicella vaccination on the incidence of herpes zoster in the general population: modelling the effect of exogenous and endogenous varicella-zoster virus immunity boosting. ( 30727971 )
2019
16
Fever and rash in an adult: Varicella re-infection in conjunction with newly diagnosed chronic lymphocytic leukemia. ( 30849382 )
2019
17
Immunogenicity and safety of the combined vaccine for measles, mumps, and rubella isolated or combined with the varicella component administered at 3-month intervals: randomised study. ( 30843921 )
2019
18
Early disappearance of maternal anti-measles, mumps, rubella, and varicella antibodies in Indian infants. ( 30765170 )
2019
19
Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: 10-year follow-up of a phase 3 multicentre, observer-blind, randomised, controlled trial. ( 30765242 )
2019
20
Long-term protection against varicella with two-dose combination measles-mumps-rubella-varicella vaccine. ( 30765245 )
2019
21
A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration. ( 30785357 )
2019
22
Vaccine strain varicella zoster virus transmitted within a family from a child with shingles results in varicella meningitis in an immunocompetent adult. ( 30680893 )
2019
23
Longitudinally Extensive Transverse Myelitis (LETM) Following Varicella Infection in a 13-Year Immunocompetent Child. ( 30598680 )
2019
24
A case report of severe recurrent varicella in an ankylosing spondylitis patient treated with adalimumab - a new side effect after 15 years of usage. ( 30732563 )
2019
25
Vaccine Strain Varicella Infection in an Infant With Previously Undiagnosed Perinatal Human Immunodeficiency Type-1 Infection. ( 30882735 )
2019
26
Live attenuated varicella-zoster virus vaccine does not induce HIV target cell activation. ( 30511963 )
2019
27
Altered immunogenicity of 23-valent pneumococcal polysaccharide vaccine in elderly patients with diabetes who revealed lower responses to concomitant administration of BIKEN varicella zoster vaccine: Results of post hoc analysis of a randomized double-blind trial. ( 30579569 )
2019
28
Efficacy, safety and immunogenicity of live attenuated varicella vaccine in healthy children in China: double-blind, randomized, placebo-controlled clinical trial. ( 30616012 )
2019
29
Presence of varicella zoster virus in zosteriform leukaemia cutis. ( 30628105 )
2019
30
Clinical and epidemiological impact of varicella infection in children prior to the introduction of the varicella vaccine in the national immunization schedule of Argentina. ( 30652441 )
2019
31
Varicella healthcare resource utilization in middle income countries: a pooled analysis of the multi-country MARVEL study in Latin America & Europe. ( 30681397 )
2019
32
Seroprevalence of varicella-zoster virus among pregnant women in Fayoum Governorate, Egypt. ( 30686830 )
2019
33
Current In Vitro Models to Study Varicella Zoster Virus Latency and Reactivation. ( 30691086 )
2019
34
Safety of live attenuated varicella-zoster vaccine in patients with underlying illnesses compared with healthy adults: a prospective cohort study. ( 30691396 )
2019
35
Serological and T Cell Responses After Varicella Zoster Virus Vaccination in HIV-Positive Patients Undergoing Renal Dialysis. ( 30694731 )
2019
36
Central nervous system varicella zoster vasculopathy in an immunocompromised patient. ( 30701156 )
2019
37
Comparison of the whole genome sequence of an Oka varicella vaccine from China with other Oka vaccine strains reveals sites putatively critical for vaccine efficacy. ( 30728261 )
2019
38
Safety and immunogenicity of a varicella vaccine without human serum albumin (HSA) versus a HSA-containing formulation administered in the second year of life: a phase III, double-blind, randomized study. ( 30732648 )
2019
39
Fatal disseminated visceral Varicella Zoster Virus infection in a renal transplant recipient. ( 30756453 )
2019
40
Effectiveness of acyclovir prophylaxis against varicella zoster virus disease after allogeneic hematopoietic cell transplantation: A systematic review and meta-analysis. ( 30756465 )
2019
41
Chemokines and matrix metalloproteinases in cerebrospinal fluid of patients with central nervous system complications caused by varicella-zoster virus. ( 30777092 )
2019
42
Varicella Zoster Virus Induces Differential Cell-Type Specific Responses in Human Corneal Epithelial Cells and Keratocytes. ( 30786281 )
2019
43
Epidemiological Impact of the Korean National Immunization Program on Varicella Incidence. ( 30804728 )
2019
44
Moyamoya syndrome as a manifestation of varicella-associated cerebral vasculopathy-case report and review of literature. ( 30805822 )
2019
45
Binding varicella zoster virus: an underestimated facet of insulin-degrading enzyme´s implication for Alzheimer´s disease pathology? ( 30806771 )
2019
46
Burden of varicella in Central and Eastern Europe: findings from a systematic literature review. ( 30810402 )
2019
47
Recombinant Glycoprotein E of Varicella Zoster Virus Contains Glycan-Peptide Motifs That Modulate B Cell Epitopes into Discrete Immunological Signatures. ( 30813247 )
2019
48
Giant cell arteritis is not associated with varicella zoster virus in temporal artery biopsies or ascending aortic resections. ( 30824633 )
2019
49
Efficient induction of cell-mediated immunity to varicella-zoster virus glycoprotein E co-lyophilized with a cationic liposome-based adjuvant in mice. ( 30827737 )
2019
50
Varicella Zoster Virus Alters Expression of Cell Adhesion Proteins in Human Perineurial Cells Via Interleukin 6. ( 30835269 )
2019
Sources

Variations for Chickenpox

About this section
Sources

Expression for Chickenpox

About this section
Search GEO for disease gene expression data for Chickenpox.
Sources

Pathways for Chickenpox

About this section
Sources

GO Terms for Chickenpox

About this section
Sources

Sources for Chickenpox

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....